Aqura Bio. offers specialist CDMO services for the scale-up and GMP manufacture of drug substances, intermediates, and advanced materials, bridging the gap between laboratory research and commercial production. Our facilities are equipped for high-purity synthesis, process optimisation, and technology transfer, ensuring seamless transition from bench to batch.
We combine deep process chemistry expertise with robust analytical and quality control systems, delivering materials that meet regulatory, safety, and reproducibility standards. Whether scaling synthetic pathways, producing clinical-grade intermediates, or refining process efficiency, our experienced teams ensure each step aligns with ICH Q7, cGMP, and ISO quality frameworks.
Supported by AI-assisted process modelling and automated reactor technologies, we streamline route development, impurity control, and scalable purification, accelerating timelines while maintaining scientific integrity. Our integrated CDMO platform accommodates small-scale pilot runs through to multi-kilogram GMP campaigns, tailored to your development needs.
From early-stage drug candidates to commercially viable processes, Aqura Bio provides flexible, compliant, and technically rigorous manufacturing solutions that empower innovation and regulatory success across the pharmaceutical, biotech, and specialty chemical sectors.